In addition, cyclin‐dependent kinase 4/6 inhibitors (CDK 4/6), poly ADP‐ribose polymerase (PARP), vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) are well‐recognized therapeutic targets that have become central to the development of drugs for BC treatment [28, 29]. The gene discussed is EGFR; the disease is breast cancer.